QPPV.COM KNOWLEDGE ASSESSMENT

Monoclonal Antibodies: Classification and Pharmacovigilance — Knowledge Assessment

Test your understanding of the concepts covered by Monoclonal Antibodies: Classification and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best reflects the regulatory relationship between monoclonal-antibody pharmacovigilance and the EU GVP framework?

Monoclonal antibodies are governed by an entirely separate pharmacovigilance system General GVP processes apply, supplemented by antibody-specific scientific knowledge and controls Only immunogenicity guidance applies to monoclonal antibodies GVP processes apply only to small-molecule medicines

Question 2 of 10 Why must disease indication and concomitant therapy be preserved in aggregate safety analyses?

They determine the product's antibody origin They may influence baseline risk, exposure, confounding, treatment interactions and benefit–risk balance They are needed only for reimbursement purposes They eliminate the need for exposure denominators

Question 3 of 10 Why is accurate medicinal-product identification essential in reports involving related biological products?

It allows product-level signal detection and prevents attribution to the wrong antibody It ensures that all products sharing a target are treated as identical It replaces the need to record treatment dates It is relevant only for financial reporting

Question 4 of 10 Which record set would best support reconstruction of a potential product-specific safety issue after a manufacturing transition?

Only the current product information and the patient's age Product and batch identifiers, administration dates, exposure sequence, clinical phenotype and manufacturing-change records Only aggregate report counts by therapeutic class Only the patient's anti-drug-antibody result

Question 5 of 10 How should a negative anti-drug-antibody result be interpreted in a suspected immune-mediated event?

It definitively excludes immunogenicity It should be interpreted with assay sensitivity, timing, drug interference and other evidence in mind It proves that the event is caused by target biology It demonstrates that the patient was never exposed

Question 6 of 10 A patient develops an event after switching from one related biological product to another. Which approach is most appropriate?

Attribute the event automatically to the newly introduced product Ignore all prior exposure because only the current product is relevant Reconstruct exposure sequence, timing, disease status, concomitant treatment and evidence for product-specific causality Treat both products as one undifferentiated exposure

Question 7 of 10 Which classification is generally most informative when developing an initial pharmacovigilance hypothesis for a monoclonal antibody?

The country in which the antibody was manufactured The antibody's historical naming convention The mechanism of action and target biology The proportion of the molecule derived from human sequences alone

Question 8 of 10 Which scenario best illustrates an on-target adverse effect?

A reaction caused solely by an incorrect product code in a safety database A physiological disturbance resulting from modulation of a target that also has an important role in normal tissue A manufacturing deviation with no evidence of patient exposure A positive anti-drug-antibody assay without any clinical finding

Question 9 of 10 A rise in adverse-event reports occurs shortly after a manufacturing-site change. What is the most appropriate initial approach?

Conclude that the site change caused the events Dismiss the pattern because causality cannot be established from spontaneous reports Integrate product identity, batch exposure, quality information, clinical phenotype and alternative explanations Assess only the number of reports without considering exposure

Question 10 of 10 Which information is particularly important when assessing an acute reaction occurring during an intravenous monoclonal-antibody infusion?

Only the antibody's origin category Timing, route, infusion conditions, premedication and clinical phenotype Only the patient's age and sex The number of unrelated antibodies authorised in the same therapeutic area

Monoclonal Antibodies: Classification and Pharmacovigilance — Knowledge Assessment

Cookie Settings